MiniMed Group (NASDAQ:MMED) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS

MiniMed Group (NASDAQ:MMED) announced its earnings results on Wednesday. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.46), Briefing.com reports. The firm had revenue of $837.00 million during the quarter. The business’s revenue for the quarter was up 15.6% on a year-over-year basis.

Here are the key takeaways from MiniMed Group’s conference call:

• MiniMed reported record fiscal 2026 revenue above $3 billion, with 8% organic growth for the year and 8.7% organic growth in Q4, driven largely by international strength and recurring revenue streams.
• U.S. Q4 growth of 1.5% fell below expectations, but management said the shortfall was mainly a timing issue tied to patients waiting for the upcoming MiniMed Flex launch rather than a demand problem.
• The company highlighted multiple product launches supporting FY2027 growth, including MiniMed Go now launched in the U.S., MiniMed Flex pre-orders underway with shipments coming later this month, and the Instinct sensor rolling out in Europe soon.
• Recurring revenue momentum continued, with CGM attachment rising to 68% in Q4 and 66% for the full year, while global pump users increased 4% year over year to 659,000.
• MiniMed guided to about 10% organic revenue growth in fiscal 2027 and an adjusted EBITDA margin of roughly 16%, saying the outlook is supported by new product launches but that growth will build progressively through the year.

MiniMed Group Stock Performance

Shares of NASDAQ:MMED opened at $14.06 on Friday. The firm’s fifty day moving average price is $12.91. MiniMed Group has a 12-month low of $10.65 and a 12-month high of $20.48.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wall Street Zen upgraded MiniMed Group to a “hold” rating in a research note on Saturday, March 14th. Barclays assumed coverage on shares of MiniMed Group in a report on Wednesday, April 1st. They issued an “overweight” rating and a $26.00 target price on the stock. Morgan Stanley began coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 price objective on the stock. Deutsche Bank Aktiengesellschaft began coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Citigroup initiated coverage on MiniMed Group in a research report on Tuesday, March 31st. They issued a “buy” rating and a $23.00 target price on the stock. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.33.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.